Biopharmaceutical and vaccines manufacturing campus of Biological E. Ltd

CM inaugurates new Biopharmaceutical and vaccines manufacturing campus of Biological E. Ltd
BE Ltd invests Rs 300 crore in phase one and expects to invest an additional Rs 250 crore over the next two or three years products

Dr. Y.S. Rajashekar Reddy, seen inaugurating the new Biopharmaceutical and Vaccines manufacturing
campus of Biological E. Ltd

Hyderabad|India|February'2009: The new Biopharmaceutical and Vaccines manufacturing campus of Hyderabad based Biological E Ltd. (Bio E) was inaugurated by the Honourable Chief Minister of Andhra Pradesh Dr Y S Rajashekar Reddy on the occasion of the inaugural ceremony of BioAsia 2009.

The new 75 acre campus is located at SP BIOTECH PARK, Phase 2 Shameerpet, outside Hyderabad. With a Phase 1 investment of over Rs. 300 crores, the facility will manufacture vaccines and biopharmaceuticals that are crucial in the global effort to prevent childhood disease. These products are intended for supply to markets worldwide including USA and Europe through our strategic partnerships.

The company has long-established expertise in the development and manufacture of vaccines and Bio E expects to invest an additional 250 crores over the next two to three years in expanding capacities and creating infrastructure for the future pipeline products of the company. Bio E's operations are driven by a strong management team whose expertise includes extensive experience in biopharmaceutical development, manufacturing and quality assurance at leading US and European biotechnology companies.

Biological E. manufactures and markets a range of vaccines and biologics including vaccines such as Tetanus (TT), Diphtheria-Tetanus-Pertussis (DTwP), Hepatitis B (HBV), Haemophilus influenza Type B (Hib), and a DTwP-HBV combination vaccine. In addition, BioE had a number of vaccines in late stage development including a novel Japanese Encephalitis Vaccine as well as a Pentavalent vaccine.

Biological E. is proud to be an active partner to the National Immunization Programme of the Government of India for over three decades with close to two billion doses of vaccine being supplied in India so far. The new facilities support Biological E's vision of creating a meaningful impact on childhood mortality and healthcare through the development and supply of high quality vaccines and biologics that are accessible to people worldwide.

Reachout's News Bureau
February' 2009

This site is conceived, designed, and maintained by ReachoutHyderabad.com.
All rights reserved world wide. Copyright © 1999- 2009. Mail your queries to reachouthyderabad@yahoo.com
Disclaimer: Neither ReachoutHyderabad.com, nor the sources it obtained the information from, are responsible for the correctness /validity of the information in these pages. It is a collection of both facts and opinions. You are advised to verify all information with a reliable source before acting on it. This disclaimer applies to all pages of ReachoutHyderabad.com. Reproduction in whole or in part in any form or medium without written permission of ReachoutHyderabad.com is prohibited.